Brief: Taiho Pharmaceutical Exercises Option For An Exclusive License To Quemliclustat In Japan And Certain Territories In Asia
08/07/2024 23:05
Arcus Biosciences Inc RCUS.N :
* TAIHO PHARMACEUTICAL EXERCISES OPTION FOR AN EXCLUSIVE
LICENSE
TO QUEMLICLUSTAT IN JAPAN AND CERTAIN TERRITORIES IN ASIA
Source text for Eikon: ID:nBw1fWDWTa
Further company coverage: RCUS.N
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering